New Presentations at American Thoracic Society 2016 Reinforce OFEV (nintedanib) Efficacy, Safety And Tolerability Across Broad Range Of Patients With IPF

INGELHEIM, Germany--(BUSINESS WIRE)--New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).1-4 In total, Boehringer Ingelheim presented 12 IPF-related abstracts at ATS, including further analyses of the INPULSIS® trials, which add to the growing body of evidence reinforcing the clinical benefit of OFEV® across a broad range of patients, by showing that:

Back to news